AU2013296218B2 - Isolating traffic-enhancing mutants of drug delivery protein - Google Patents

Isolating traffic-enhancing mutants of drug delivery protein Download PDF

Info

Publication number
AU2013296218B2
AU2013296218B2 AU2013296218A AU2013296218A AU2013296218B2 AU 2013296218 B2 AU2013296218 B2 AU 2013296218B2 AU 2013296218 A AU2013296218 A AU 2013296218A AU 2013296218 A AU2013296218 A AU 2013296218A AU 2013296218 B2 AU2013296218 B2 AU 2013296218B2
Authority
AU
Australia
Prior art keywords
seq
penton base
polypeptide
carrier
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2013296218A
Other languages
English (en)
Other versions
AU2013296218A1 (en
Inventor
Lali K. Medina-Kauwe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cedars Sinai Medical Center
Original Assignee
Cedars Sinai Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cedars Sinai Medical Center filed Critical Cedars Sinai Medical Center
Publication of AU2013296218A1 publication Critical patent/AU2013296218A1/en
Priority to AU2019204815A priority Critical patent/AU2019204815A1/en
Application granted granted Critical
Publication of AU2013296218B2 publication Critical patent/AU2013296218B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/075—Adenoviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1058—Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Ecology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2013296218A 2012-08-03 2013-08-02 Isolating traffic-enhancing mutants of drug delivery protein Ceased AU2013296218B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2019204815A AU2019204815A1 (en) 2012-08-03 2019-07-04 Isolating Traffic-Enhancing Mutants Of Drug Delivery Protein

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261679306P 2012-08-03 2012-08-03
US61/679,306 2012-08-03
PCT/US2013/053493 WO2014022811A1 (en) 2012-08-03 2013-08-02 Isolating traffic-enhancing mutants of drug delivery protein

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2019204815A Division AU2019204815A1 (en) 2012-08-03 2019-07-04 Isolating Traffic-Enhancing Mutants Of Drug Delivery Protein

Publications (2)

Publication Number Publication Date
AU2013296218A1 AU2013296218A1 (en) 2015-02-19
AU2013296218B2 true AU2013296218B2 (en) 2019-07-18

Family

ID=50028570

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2013296218A Ceased AU2013296218B2 (en) 2012-08-03 2013-08-02 Isolating traffic-enhancing mutants of drug delivery protein
AU2019204815A Abandoned AU2019204815A1 (en) 2012-08-03 2019-07-04 Isolating Traffic-Enhancing Mutants Of Drug Delivery Protein

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2019204815A Abandoned AU2019204815A1 (en) 2012-08-03 2019-07-04 Isolating Traffic-Enhancing Mutants Of Drug Delivery Protein

Country Status (18)

Country Link
US (2) US10036009B2 (enExample)
EP (1) EP2880160B1 (enExample)
JP (2) JP6618360B2 (enExample)
KR (1) KR102115630B1 (enExample)
CN (1) CN104619839A (enExample)
AU (2) AU2013296218B2 (enExample)
BR (1) BR112015002004A2 (enExample)
CA (1) CA2881582A1 (enExample)
DK (1) DK2880160T3 (enExample)
ES (1) ES2703052T3 (enExample)
IL (1) IL236955A0 (enExample)
IN (1) IN2015DN01196A (enExample)
MX (1) MX366347B (enExample)
PL (1) PL2880160T3 (enExample)
PT (1) PT2880160T (enExample)
RU (1) RU2015105052A (enExample)
WO (1) WO2014022811A1 (enExample)
ZA (1) ZA201500739B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9078927B2 (en) 2007-07-06 2015-07-14 Cedars-Sinai Medical Center Self-assembling complex for targeting chemical agents to cells
WO2010085665A2 (en) 2009-01-23 2010-07-29 Cedars-Sinai Medical Center Targeted delivery system
CN104619839A (zh) 2012-08-03 2015-05-13 西塞医疗中心 药物递送蛋白质的增强运输的突变体的分离
RU2674146C2 (ru) 2013-05-08 2018-12-07 Седарс-Синай Медикал Центр Нацеленные корролы, проявляющие опухолевую токсичность и предназначенные для мрт
RU2682335C2 (ru) 2014-01-17 2019-03-19 Сидарс-Синай Медикал Сентр Рецептор-направленные конструкции и их применение
MX2016013025A (es) 2014-04-04 2017-04-27 Cedars Sinai Medical Center Focalizacion de cancer de mama her2+ resistente a trastuzumab con una nanoparticula dirigida de her3.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009009441A2 (en) * 2007-07-06 2009-01-15 Cedars-Sinai Medical Center Self-assembling complex for targeting chemical agents to cells
US20120004181A1 (en) * 2009-01-23 2012-01-05 Cedars-Sinai Medical Center Targeted delivery system

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5439829A (en) 1991-01-30 1995-08-08 Eli Lilly And Company Immobilization of biologically active molecules by changing the Oxidation state of a chelated transition metal ion
US6287792B1 (en) 1991-06-17 2001-09-11 The Regents Of The University Of California Drug delivery of antisense oligonucleotides and peptides to tissues in vivo and to cells using avidin-biotin technology
GB9223084D0 (en) 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
US5547945A (en) 1993-07-15 1996-08-20 Jcr Pharmaceuticals Co., Ltd. Remitting agent for nephrotic syndrome and hepatopathy symptoms
US6465253B1 (en) * 1994-09-08 2002-10-15 Genvec, Inc. Vectors and methods for gene transfer to cells
US5559099A (en) * 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US6066322A (en) 1995-03-03 2000-05-23 Millennium Pharmaceuticals, Inc. Methods for the treatment of immune disorders
IL124654A0 (en) 1995-11-28 1998-12-06 Genvec Inc Vectors and method for gene transfer to cells
JP4515542B2 (ja) * 1997-02-10 2010-08-04 ジェネンテック， インコーポレイテッド ヒレグリン変異体
GB9709421D0 (en) 1997-05-10 1997-07-02 Zeneca Ltd Chemical compounds
AU760766B2 (en) 1998-08-18 2003-05-22 Regents Of The University Of California, The Preventing airway mucus production by administration of EGF-R antagonists
US6333396B1 (en) 1998-10-20 2001-12-25 Enzon, Inc. Method for targeted delivery of nucleic acids
CA2391534A1 (en) 1999-11-15 2001-05-25 Drug Innovation & Design, Inc. Selective cellular targeting: multifunctional delivery vehicles
CA2415319A1 (en) 2000-06-16 2001-12-20 Martek Biosciences Corporation Recombinant phycobiliprotein and phycobiliprotein linker fusion proteins and uses therefore
IT1318704B1 (it) * 2000-09-22 2003-08-27 Consorzio Interuniversitario P Vettori chimerici e loro uso per il trasferimento di geni eterologhi.
AU2002240201A1 (en) 2001-02-02 2002-08-19 Yale University Peptides for facilitating composite receptor expression and translocation of macromolecules
EP1266963A1 (en) * 2001-06-15 2002-12-18 Crucell Holland B.V. Chimaeric phages
SE0201863D0 (en) 2002-06-18 2002-06-18 Cepep Ab Cell penetrating peptides
US7329638B2 (en) 2003-04-30 2008-02-12 The Regents Of The University Of Michigan Drug delivery compositions
US7205387B2 (en) 2003-08-28 2007-04-17 Agency For Science, Technology And Research Recombinant polypeptide useful for neurotrophin receptor mediated gene delivery and as neurotrophin agonist
US20060014712A1 (en) 2004-05-30 2006-01-19 Cemines, Inc. Controlled delivery of therapeutic compounds
US8057821B2 (en) 2004-11-03 2011-11-15 Egen, Inc. Biodegradable cross-linked cationic multi-block copolymers for gene delivery and methods of making thereof
US20110052697A1 (en) 2006-05-17 2011-03-03 Gwangju Institute Of Science & Technology Aptamer-Directed Drug Delivery
JP4479755B2 (ja) 2007-07-03 2010-06-09 ソニー株式会社 有機エレクトロルミネッセンス素子、及び、有機エレクトロルミネッセンス表示装置
CN101883858B (zh) * 2007-11-28 2015-07-22 宾夕法尼亚大学托管会 猿猴亚家族E腺病毒SAdV-39、-25.2、-26、-30、-37和-38及其应用
WO2013052859A2 (en) 2011-10-05 2013-04-11 Genvec, Inc. Adenoviral vector-based respiratory syncytial virus (rsv) vaccine
CN104619839A (zh) 2012-08-03 2015-05-13 西塞医疗中心 药物递送蛋白质的增强运输的突变体的分离
RU2674146C2 (ru) 2013-05-08 2018-12-07 Седарс-Синай Медикал Центр Нацеленные корролы, проявляющие опухолевую токсичность и предназначенные для мрт
RU2682335C2 (ru) * 2014-01-17 2019-03-19 Сидарс-Синай Медикал Сентр Рецептор-направленные конструкции и их применение
MX2016013025A (es) * 2014-04-04 2017-04-27 Cedars Sinai Medical Center Focalizacion de cancer de mama her2+ resistente a trastuzumab con una nanoparticula dirigida de her3.
MX2018014576A (es) * 2016-05-27 2019-06-06 Cedars Sinai Medical Center Nanopartículas para el suministro de fármaco y tratamientos para el cáncer resistente a fármacos.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009009441A2 (en) * 2007-07-06 2009-01-15 Cedars-Sinai Medical Center Self-assembling complex for targeting chemical agents to cells
US20120004181A1 (en) * 2009-01-23 2012-01-05 Cedars-Sinai Medical Center Targeted delivery system

Also Published As

Publication number Publication date
BR112015002004A2 (pt) 2017-07-04
CA2881582A1 (en) 2014-02-06
DK2880160T3 (en) 2019-01-14
WO2014022811A1 (en) 2014-02-06
IN2015DN01196A (enExample) 2015-06-26
US10036009B2 (en) 2018-07-31
KR102115630B1 (ko) 2020-05-27
MX366347B (es) 2019-07-05
RU2015105052A (ru) 2016-09-27
AU2013296218A1 (en) 2015-02-19
AU2019204815A1 (en) 2019-07-25
KR20150038543A (ko) 2015-04-08
JP6618360B2 (ja) 2019-12-11
US10752893B2 (en) 2020-08-25
EP2880160A1 (en) 2015-06-10
JP2015527343A (ja) 2015-09-17
US20150240231A1 (en) 2015-08-27
IL236955A0 (en) 2015-03-31
PL2880160T3 (pl) 2019-03-29
PT2880160T (pt) 2018-12-17
CN104619839A (zh) 2015-05-13
US20180298376A1 (en) 2018-10-18
ZA201500739B (en) 2018-07-25
EP2880160A4 (en) 2016-04-20
MX2015001366A (es) 2015-08-13
EP2880160B1 (en) 2018-09-19
ES2703052T3 (es) 2019-03-06
JP2020002138A (ja) 2020-01-09

Similar Documents

Publication Publication Date Title
US10752893B2 (en) Isolating traffic-enhancing mutants of drug delivery protein
CN111629760B (zh) 包含rna治疗剂的外泌体
Nicastro et al. Bacteriophage lambda display systems: developments and applications
US8729038B2 (en) Down regulation of the gene expression by means of nucleic acid-loaded virus-like particles
US20150010475A1 (en) Crlf-2 binding peptides, protocells and viral-like particles useful in the treatment of cancer, including acute lymphoblastic leukemia (all)
ES2871400T3 (es) Células inmunitarias deficientes en SUV39H1
CN113347993A (zh) 突变牛痘病毒及其用途
US9879254B2 (en) Targeting RNAs to microvesicles
JPWO2013018778A1 (ja) ウィルムス腫瘍遺伝子産物またはその断片をコードしている改変型核酸構築物を含んでいる免疫治療用細胞、当該細胞の製造方法、および当該核酸構築物
KR20180092989A (ko) 트랜스포존 시스템, 이를 포함한 키트, 및 이들의 용도
CN115484990A (zh) 诱导具有基因组序列变异的细胞凋亡的组合物及使用组合物诱导细胞凋亡的方法
CN109563490A (zh) 具有经修饰的糖蛋白b的疱疹病毒
KR20200006111A (ko) 세포외 소포에 화학적 및 생물학적 제제/분자를 로딩하기 위한 조성물 및 방법
US20250057956A1 (en) Cell-type specific targeting contractile injection system
WO2024230738A1 (zh) 外囊泡融合蛋白及其应用
KR20200041185A (ko) 세포 투과성 펩타이드 및 이의 고속 대량 스크리닝 방법
JP2024503728A (ja) 様々な状態を処置するためのペプチド治療薬を同定する方法
US20250082679A1 (en) Method of Targeting Cells and Associated Compositions
Ikwuagwu Systematic Engineering of Virus-Like Particles to Identify Self-Assembly Rules for Biotechnological Applications
WO2025260044A1 (en) Ligand-directed gene editing approaches
Kritz Peptides from phage display libraries for targeted gene delivery via the p75NTR neurotrophic receptor

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired